download
FREE KOL List
    • KOL
    • KOLs Community
    • Cystic
    • Cystic Fibrosis
    • Michael R Knowles
    • Michael R Knowles

      Michael R Knowles

      Marsico Lung Institute/UNC CF Research Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA | School of Medicine, University of ...

       

       

      KOL Resume for Michael R Knowles

      Year
      2022

      Marsico Lung Institute/UNC CF Research Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

      School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

      2021

      Department of Medicine

      Marsico Lung Institute, University of North Carolina, Chapel Hill, NC 27599

      2020

      Marsico Lung Institute, University of North Carolina at Chapel Hill School of Medicine Cystic Fibrosis/Pulmonary Research & Treatment Center, Chapel Hill, North Carolina, United States of America

      University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

      2019

      Marsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

      Cystic Fibrosis/Pulmonary Research and Treatment Center, University of North Carolina, Chapel Hill, NC 27599, USA

      University of North Carolina at Chapel Hill.

      2018

      Marsico Lung Institute/UNC CF Research Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North, Carolina, 27599, USA.

      Cystic Fibrosis Pulmonary Research and Treatment Center, University of North Carolina, Chapel Hill, NC, USA

      9 Department of Medicine.

      11 University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina.

      2017

      2 Cystic Fibrosis/Pulmonary Research and Treatment Center, Marsico Lung Institute, School of Medicine, and.

      University of North Carolina at Chapel Hill, Marisco Lung Institute, Chapel Hill, NC, United States of America

      2016

      9 Department of Medicine, University of North Carolina, Chapel Hill, North Carolina.

      Marsico Lung Institute/Cystic Fibrosis Research Center, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

      2015

      Marsico Lung Institute/UNC CF Research Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA

      Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

      2014

      Department of Cell & Molecular Physiology of Medicine, University of North Carolina, Chapel Hill, North Carolina, United States of America

      Cystic Fibrosis/Pulmonary Research and Treatment Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

      2013

      Cystic Fibrosis/Pulmonary Research and Treatment Center,

      Department of Medicine,

      University College London (UCL) Institute of Child Health Molecular Medicine Unit and Birth Defects Research Centre London UK

      2012

      Cystic Fibrosis/Pulmonary Research and Treatment Center, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America

      From the Laboratory of Developmental Biology (N.N., R.F., R.A.G., S.K., B.C., S.L.S., M.S., N.K., L.L., C.W.L.), Office of Biostatistics Research (X.T.), Electron Microscopy Core (P.S.C., M.P.D.), National Heart Lung Blood Institute, Bethesda, MD; Department of Developmental Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA (R.F., Y.L., H.Y., O.K., B.C., A.S., C.W.L.); Department of Human Genetics, University of Pittsburgh School of Public Health, Pittsburgh, PA (M.B.); Departments of Pathology and Laboratory Medicine (M.A.Z., K.B.), Department of Medicine (M.K.), Division of Pediatric Pulmonology (K.K.C., M.L.), University of North Carolina Chapel Hill, Chapel Hill, NC; Department of Cardiology (K.K., L.L.), Division of Pulmonary and Sleep Medicine (N.N., S.K., I.S.), Department of Cardiac Surgery, Children's National Medical Center, Washington, DC (R.J.); Universitätsklinikum Münster, Klinik und Poliklinik für Kinder- und Jugendmedizin, Allgemeine Pädiatrie, Münster; Germany (H.O.); National Institute of Allergy and Infectious Disease (K.O.), Howard Hughes Medical Institute (R.A.G., M.S.), National Institutes of Health Research Scholars Program, Bethesda, MD; Current address: Division of Pediatric Pulmonology, Jersey Shore University Medical Center, Neptune, NJ (N.N.).

      Department of Internal Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA

      2011

      Cystic Fibrosis, Pulmonary Research, and Treatment Center, School of Medicine, University of North Carolina, Chapel Hill, NC 27599; and

      Division of Pulmonary Medicine, Department of Internal Medicine, University of North Carolina at Chapel Hill, Chapel Hill North Carolina

      2010

      Department of Biostatistics, Center for Environmental Bioinformatics, and, UNC Pulmonary and CF Research Center, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, N.C., USA

      Professor of Medicine, University of California, San Francisco, Chief, Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, San Francisco, California

      2009

      Cystic Fibrosis-Pulmonary Research and Treatment Center, University of North Carolina, Chapel Hill, North Carolina; and

      Division of Pulmonary Medicine, Department of Internal Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

      2008

      Cystic Fibrosis Pulmonary Research Treatment Center, University of North Carolina, Chapel Hill, NC, USA

       

       

      Michael R Knowles: Influence Statistics

      Sample of concepts for which Michael R Knowles is among the top experts in the world.
      Concept World rank
      asymmetric targeting #1
      pcd mutations #1
      pcd clinical phenotype #1
      modified infant method #1
      ciliary dyskinesia amish #1
      agtr2 absence #1
      pcd breath tests #1
      interactions dhcs #1
      ida mtd #1
      illness sputum tomography #1
      diseasereflecting dysfunction #1
      cfap57 #1
      rsph4a patients #1
      cftr f508del variant #1
      biology pcd #1
      gas2l2 #1
      pcd rsi #1
      pcd foundation guidance #1
      uncharacterized gene cfap57 #1
      pcd genes dnai1 #1
      genetic subset analysis #1
      randomization body asymmetry #1
      mutations dnai1 #1
      autosomal dominant variants #1
      rsph4a cilia #1
      subsequent severity #1
      individuals sinopulmonary disease #1
      clearance airway surfaces #1
      ciliary ultrastructural analyses #1
      regionbased burden testing #1
      dnai1 13 families #1
      ciliary ultrastructural defects #1
      allele occurs #1
      omron neuo7 #1
      robust clinical phenotype #1
      cfld 9 polymorphisms #1
      dnah5 c7502gc mutation #1
      msra null alleles #1
      systemic steroids sixteen #1
      disease primary ciliary #1
      rsph4a human cilia #1
      foundation registry data #1
      7t 3849 10kb #1
      airway retention addition #1
      nasal aminoglycosides patients #1
      pseudomonas lung function #1
      subjects ciliary inclusions #1
      mv maximum baseline #1
      reduced betaenac expression #1

       

      Prominent publications by Michael R Knowles

      KOL-Index: 17311

      BACKGROUND: Abnormal homeostasis of the volume of airway surface liquid in patients with cystic fibrosis is thought to produce defects in mucus clearance and airway defense. Through osmotic forces, hypertonic saline may increase the volume of airway surface liquid, restore mucus clearance, and improve lung function.

      METHODS: A total of 24 patients with cystic fibrosis were randomly assigned to receive treatment with inhaled hypertonic saline (5 ml of 7 percent sodium chloride) four times ...

      Known for Mucus Clearance | Hypertonic Saline | Lung Function | Cystic Fibrosis | Airway Surface Liquid
      KOL-Index: 15893

      BACKGROUND: Cystic fibrosis is characterized by abnormal electrolyte transport across the epithelia of the airways. In particular, there is excessive sodium absorption and deficient chloride secretion. Drugs that block excessive sodium absorption may provide clinical benefit in cystic fibrosis, but there are no available therapeutic agents to improve chloride secretion. In vitro studies in cultured human-airway epithelia indicate that triphosphate nucleotides (ATP and UTP) induce ...

      Known for Cystic Fibrosis | Chloride Secretion | Extracellular Nucleotides | Atp Utp | Apical Membrane
      KOL-Index: 15660

      BACKGROUND: Many patients with chronic pulmonary disease similar to that seen in cystic fibrosis have normal (or nondiagnostic) sweat chloride values. It has been difficult to make the diagnosis of cystic fibrosis in these patients because no associated mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene has been identified.

      METHODS: We evaluated 23 patients with pulmonary disease characteristic of cystic fibrosis but with sweat chloride concentrations in the ...

      Known for Cystic Fibrosis | Sweat Chloride | Patients Mutation | Intron Cftr Gene | Human Pair
      KOL-Index: 15069

      RATIONALE: Primary ciliary dyskinesia (PCD) is an autosomal recessive, genetically heterogeneous disorder characterised by oto-sino-pulmonary disease and situs abnormalities (Kartagener syndrome) due to abnormal structure and/or function of cilia. Most patients currently recognised to have PCD have ultrastructural defects of cilia; however, some patients have clinical manifestations of PCD and low levels of nasal nitric oxide, but normal ultrastructure, including a few patients with ...

      Known for Pcd Patients | Ciliary Ultrastructure | Biallelic Mutations | Situs Abnormalities | Function Cilia
      KOL-Index: 14847

      RATIONALE: Primary ciliary dyskinesia (PCD) is a genetically heterogeneous disorder characterized by recurrent infections of the airways and situs inversus in half of the affected offspring. The most frequent genetic defects comprise recessive mutations of DNAH5 and DNAI1, which encode outer dynein arm (ODA) components. Diagnosis of PCD usually relies on electron microscopy, which is technically demanding and sometimes difficult to interpret.

      METHODS: Using specific antibodies, we ...

      Known for Respiratory Cells | Primary Ciliary | Patients Pcd | Oda Defects | Electron Microscopy
      KOL-Index: 14559

      BACKGROUND: Cystic fibrosis is a monogenic disease that deranges multiple systems of ion transport in the airways, culminating in chronic infection and destruction of the lung. The introduction of a normal copy of the cystic fibrosis transmembrane conductance regulator (CFTR) gene into the airway epithelium through gene transfer is an attractive approach to correcting the underlying defects in patients with cystic fibrosis. We tested the feasibility of gene therapy using adenoviral ...

      Known for Gene Transfer | Cystic Fibrosis | Nasal Epithelium | Adenoviral Vector | Ion Transport
      KOL-Index: 14093

      RATIONALE: Primary ciliary dyskinesia (PCD) is characterized by recurrent airway infections and randomization of left-right body asymmetry. To date, autosomal recessive mutations have only been identified in a small number of patients involving DNAI1 and DNAH5, which encode outer dynein arm components.

      METHODS: We screened 109 white PCD families originating from Europe and North America for presence of DNAH5 mutations by haplotype analyses and/or sequencing.

      RESULTS: Haplotype analyses ...

      Known for Dnah5 Mutations | Dynein Arm | Primary Ciliary Dyskinesia | North America | Patients Pcd
      KOL-Index: 13540

      BACKGROUND: It is unknown whether genetic factors predispose patients to idiopathic pancreatitis. In patients with cystic fibrosis, mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene typically cause pulmonary and pancreatic insufficiency while rarely causing pancreatitis. We examined whether idiopathic pancreatitis is associated with CFTR mutations in persons who do not have lung disease of cystic fibrosis.

      METHODS: We studied 27 patients (mean age at ...

      Known for Cystic Fibrosis | Patients Pancreatitis | Mutations Cftr Gene | Lung Disease | 5t Allele
      KOL-Index: 13503

      BACKGROUND & AIMS: Nonalcoholic chronic pancreatitis is usually idiopathic and often associated with cystic fibrosis gene (CFTR) mutations. It is unknown whether pancreatitis risk correlates with having 1 or 2 CFTR mutations, abnormal epithelial ion transport, or mutations of other genes.

      METHODS: We tested 39 patients with idiopathic chronic pancreatitis (mean age at diagnosis, 33 years) for common mutations of CFTR and of genes encoding a trypsin inhibitor (PSTI) and trypsinogen ...

      Known for Pancreatitis Risk | Cystic Fibrosis | Trypsin Inhibitor | Gene Mutations | Ion Transport
      KOL-Index: 13289

      Cystic fibrosis (CF) is a monogenetic disease that is associated with chronic airways disease and early death. The pulmonary disease reflects mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, and associated abnormal epithelial ion transport, including defective cAMP-mediated (CFTR) Cl- secretion and an accelerated rate of basal Na+ transport. With the development of vectors for gene therapy, the airway epithelium of CF patients has been targeted for ...

      Known for Gene Transfer | Cystic Fibrosis | Vivo Nasal | Potential Difference | Ion Transport
      KOL-Index: 12917

      RATIONALE: Primary ciliary dyskinesia (PCD) is a rare, usually autosomal recessive, genetic disorder characterized by ciliary dysfunction, sino-pulmonary disease, and situs inversus. Disease-causing mutations have been reported in DNAI1 and DNAH5 encoding outer dynein arm (ODA) proteins of cilia.

      OBJECTIVES: We analyzed DNAI1 to identify disease-causing mutations in PCD and to determine if the previously reported IVS1+2_3insT (219+3insT) mutation represents a "founder" or "hot spot" ...

      Known for Ciliary Dyskinesia | Mutations Dnai1 | Patients Pcd | Polymerase Chain | Dyneins Child
      KOL-Index: 12087

      Primary ciliary dyskinesia (PCD) is a genetically heterogeneous, autosomal-recessive disorder, characterized by oto-sino-pulmonary disease and situs abnormalities. PCD-causing mutations have been identified in 20 genes, but collectively they account for only ∼65% of all PCDs. To identify mutations in additional genes that cause PCD, we performed exome sequencing on three unrelated probands with ciliary outer and inner dynein arm (ODA+IDA) defects. Mutations in SPAG1 were identified in ...

      Known for Dynein Arms | Primary Ciliary | Mutations Spag1 | Situs Abnormalities | Cytoplasmic Assembly
      KOL-Index: 12030

      We studied the change in ion transport function by measuring the basal transepithelial potential difference (PD) across the ciliated epithelium of the nose in 85 term neonates during the first 72 hours of life. Differences in PD associated with the mode of delivery or the presence of respiratory disease and differences in the PD response to the superfusion of amiloride (10(-5) mol/L) were assessed. We also studied term neonates with transient tachypnea of the newborn (TTN) and acute ...

      Known for Transient Tachypnea | Ion Transport | Nasal Epithelium | Neonates Ttn | Electrical Potential Difference
      KOL-Index: 11880

      Hemoptysis is common in patients with cystic fibrosis (CF). Bleeding may vary in severity, ranging from minor blood-streaking of sputum to expectoration of significant quantities of blood. Major hemoptysis, defined as bleeding greater than 240 ml/24 h, represents a medical emergency. Bronchial artery embolization (BAE) is one of the treatment options for hemoptysis. We reviewed the 10-yr experience at the University of North Carolina Hospitals in the treatment of hemoptysis by BAE. ...

      Known for Bae Patients | Bronchial Artery Embolization | Cystic Fibrosis | Treatment Hemoptysis | Adult Angiography

      Key People For Cystic Fibrosis

      Top KOLs in the world
      #1
      Bonnie Watts Ramsey
      cystic fibrosis pseudomonas aeruginosa young children
      #2
      Michael W Konstan
      cystic fibrosis lung function dornase alfa
      #3
      Mary L Corey
      cystic fibrosis pulmonary function meconium ileus
      #4
      Lap‐Chee Tsui
      cystic fibrosis situ hybridization human pair
      #5
      Felix A Ratjen
      cystic fibrosis pseudomonas aeruginosa lung function
      #6
      Frank J Accurso
      cystic fibrosis lung function newborn screening

      Michael R Knowles:Expert Impact

      Concepts for whichMichael R Knowleshas direct influence:Cystic fibrosis,  Primary ciliary dyskinesia,  Lung disease,  Ciliary dyskinesia,  Primary ciliary,  Lung function,  Patients cystic fibrosis,  Gene transfer.

      Michael R Knowles:KOL impact

      Concepts related to the work of other authors for whichfor which Michael R Knowles has influence:Cystic fibrosis,  Primary ciliary dyskinesia,  Chronic pancreatitis,  Epithelial cells,  Lung disease,  Pseudomonas aeruginosa,  Gene therapy.


       

      Tools

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile


      Marsico Lung Institute/UNC CF Research Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA | School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States | University

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.